Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Open accessThe DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Abstract
Poly-(ADP-ribose) polymerase (PARP) inhibitors act through synthetic lethality in cells with defects in homologous recombination (HR) DNA repair caused by molecular aberrations such as BRCA mutations, and is approved for treatment in ovarian cancer, with promising clinical activity against other HR defective tumors including breast and prostate cancers. Three PARP inhibitors have been FDA approved, while another two have shown promising activity and are in late stage development. Nonetheless, both primary and secondary resistance to PARP inhibition have led to treatment failure, and the development of predictive biomarkers and the ability to identify and overcome mechanisms of resistance is vital for optimization of its clinical utility. Additionally, there has been evidence that PARP inhibition may have a therapeutic role beyond HR deficient tumors which warrants further investigation, both as single agent and in combination with other therapeutic modalities like cytotoxic chemotherapy, radiation, targeted therapy and immunotherapy. With new strategies to overcome resistance and expand its therapeutic utility, PARP inhibitors are likely to become a staple in our armamentarium of drugs in cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, resistance inevitably emerges during its clinical application, which can lead to cancer progression and reduced survival rates, posing a substantial challenge in clinical management [31].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 7×
“Olaparib was first shown in simultaneous publications from two independent groups to successfully induce cell killing effects in BRCA-deficient cancer cells through inhibition of DDR [12,13].”
BackgroundInfluentialSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 7×
“Olaparib was first shown in simultaneous publications from two independent groups to successfully induce cell killing effects in BRCA-deficient cancer cells through inhibition of DDR [12,13].”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · cited 1×
“Phase I studies subsequently demonstrated good safety and tolerability up to a dose of 400 mg twice daily, with dose limiting toxicities of grade 4 thrombocytopenia and grade 3 somnolence, and also showed early signals of antitumor activity with a response rate of up to 46% in heavily pre-treated BRCA1/2-mutant cancer…”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882 · cited 1×
“DSBs are repaired through 2 major pathways, the high fidelity HR pathway, and the more error-prone non-homologous end-joining (NHEJ) pathway [7].”
BackgroundPARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 1×
“PARP inhibitors profoundly sensitize cancer cells to DNA damaging agents and act through synthetic lethality in cells with defects in homologous recombination (HR) DNA repair caused by molecular aberrations such as BRCA1/2 mutations [2].”
BackgroundSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“A systemic screen of cancer cell lines with a large panel of drugs revelaed that Ewing’s sarcoma cells harboring the EWSR10FLI1 gene translocation was exquisitely sensitive to PARP inhibitors [48].”
BackgroundNiraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451 · cited 1×
“In this study, patients with platinum-sensitive disease were included regardless of germline BRCA1/2 mutation and HR deficiency status, while results were stratified to investigate role of HR deficiency biomarkers for response [27].”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · cited 1×
“for patients with platinum sensitive compared to platinum resistant disease [16,17].”
BackgroundTrapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192 · cited 2×
“Emerging evidence also suggests that in addition to the catalytic action of PARP inhibitors leading to synthetic lethality in HR deficient tumors, PARP inhibitors also causes trapping of PARP1 and PARP2, forming PARP-DNA complexes with increased cytotoxicity leading to increased cell killing [9].”
Background
Cited by
van den Heerik, A. S. V. M., Horeweg, N., de Boer, S. M., Bosse, T., & Creutzberg, C. L. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001822 · Cited by 197
Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018) · Medicines · doi:10.3390/medicines5010016 · Cited by 188
“Strategies to bypass this resistance may imply alternate dosing of PARP inhibitors or combined administration with platinum derivatives [346].”
BackgroundDNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovicova, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 168
Jain, P. G., & Patel, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.024 · Cited by 142
Haynes, B. M., Murai, J., & Lee, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.003 · Cited by 150
Mekonnen, N., Yang, H., & Shin, Y. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880643 · Cited by 137
Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
Revythis, A., Limbu, A., Mikropoulos, C., Ghose, A., Sanchez, E., Sheriff, M., & Boussios, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19148577 · Cited by 117
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
Post, C., Westermann, A. M., Bosse, T., Creutzberg, C. L., & Kroep, J. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102973 · Cited by 67
“Generally, HRD tumors are likely to respond to PARP inhibitors (Lim and Tan, 2017).”
PARP inhibitors in gastric cancer: beacon of hope
Wang, Y., Zheng, K., Huang, Y., Xiong, H., Su, J., Chen, R., & Zou, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02005-6 · Cited by 66
“A better understanding of PARP inhibitor resistance and the underlying mechanisms involved in its mechanism of action will also help in the development of new therapeutic strategies to address this issue [108].”
BackgroundDNA Repair: Translation to the Clinic
Minten, E. V., & Yu, D. S. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.02.007 · Cited by 39
Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer
Shen, K., Yang, L., Li, F., Zhang, F., Ding, L., Yang, J., Lu, J., Wang, N., & Wang, Y. (2021) · Current Drug Targets · doi:10.2174/1389450122666210617111304 · Cited by 34
Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer
Eskiler, G. G., Çeçener, G., Egelí, Ü., & Tunca, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29552 · Cited by 34
PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer
Hirschl, N., Leveque, W., Granitto, J., Sammarco, V., Fontillas, M., & Penson, R. T. (2024) · Cancers · doi:10.3390/cancers16050932 · Cited by 34
“…PARP inhibition correlates with the duration of the binding of the drug at the replication fork at DNA repair and is nicely reviewed by Lim and Tan [4] inhibition correlates with the duration of the binding of the drug at the replication fork at DNA repair and is nicely reviewed by Lim and Tan [4]”
BackgroundDrug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration
Sahaboglu, A., Miranda, M., Canjuga, D., Avci‐Adali, M., Savytska, N., Secer, E., Pliego, J. A. F., Kayık, G., & Durdağı, S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03283-2 · Cited by 29
The Impact of DNA Repair Pathways in Cancer Biology and Therapy
Nikolaev, A. Y., & Yang, E. S.-H. (2017) · Cancers · doi:10.3390/cancers9090126 · Cited by 24
Bertucci, F., Finetti, P., Monneur, A., Perrot, D., Chevreau, C., Cesne, A. L., Blay, J., Mir, O., & Birnbaum, D. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12522 · Cited by 30
Bhattacharjee, S., Sullivan, M. J., Wynn, R. R., Demagall, A., Hendrix, A. S., Sindhwani, P., Petros, F. G., & Nadiminty, N. (2022) · BMC Cancer · doi:10.1186/s12885-022-09376-9 · Cited by 23
“is almost purely a catalytic inhibitor, while talazoparib is primarily a PARP-trapper [41].”
BackgroundInfluentialZhang, G., Liu, C., Bai, H., Cao, G., Cui, R., & Zhang, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.9902 · Cited by 24
“However, there remains a substantial number of patients with mutations that resist this agent (39).”
Novel therapeutics: response and resistance in ovarian cancer
Zamarin, D. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000456 · Cited by 23
“A number of studies uncovered several new mechanisms of PARP inhibitor resistance.(8) Dr Neil Johnson presented an oral abstract describing a novel mechanism responsible for acquired PARP inhibitor resistance.”
BackgroundLip, H., Amini, M. A., Zetrini, A., Cai, P., Abbasi, A. Z., Bristow, R. G., Rauth, A. M., & Wu, X. Y. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.02.026 · Cited by 21
Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Mangoni, M., Sottili, M., Salvatore, G., Campanacci, D. A., Scoccianti, G., Beltrami, G., Paoli, C. D., Dominici, L., Maragna, V., Olmetto, E., et al. (2018) · La radiologia medica · doi:10.1007/s11547-018-0877-4 · Cited by 17
Dual-Target Inhibitors Based on PARP1: New Trend in the Development of Anticancer Research
Ge, J., Yin, Y., Li, Y., Deng, Y., & Fu, H. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0292 · Cited by 16
The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers
Lheureux, S., Mirza, M. R., & Coleman, R. L. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00347 · Cited by 18
Li, X., Zhang, Y., Chai, X., Zhou, S., Zhang, H., He, J., Zhou, R., Cai, L., Chen, L., & Tao, G. (2019) · PubMed Central · Cited by 16
Emerging PARP inhibitors for treating breast cancer
Robert, M., Patsouris, A., Frenel, J., Gourmelon, C., Augereau, P., & Campone, M. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1527900 · Cited by 14
Wang, L., Wang, Q., Xu, Y., Cui, M., & Han, L. (2019) · Current Drug Targets · doi:10.2174/1389450120666190925123507 · Cited by 14
Lorentzian, A. C., Rever, J., Ergin, E. K., Guo, M., Akella, N. M., Rolf, N., Lim, C. J., Reid, G. S. D., Maxwell, C. A., & Lange, P. F. (2023) · Nature Communications · doi:10.1038/s41467-023-42701-9 · Cited by 13
“We selected to further characterize PARP1 as a candidate target since PARP1/2 inhibitors are already developmental therapeutics for a variety of pediatric tumors 17 .”
BackgroundHuang, M., Chen, L., Ma, X., & Xu, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03542-8 · Cited by 9
“However, resistance inevitably emerges during its clinical application, which can lead to cancer progression and reduced survival rates, posing a substantial challenge in clinical management [31].”
BackgroundHuman Population Genetics/Genomics and Society
Templeton, A. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-386025-5.00014-2 · Cited by 9
Zhang, Y. L., Lu, Y., Li, S., Zheng, F., Dong, Y., Tang, H., Wang, X., & Wang, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102392 · Cited by 17
“…– 50], radiotherapy (for locally advanced, 40 – 60 % 5-yr survival but with toxicity and radioresistance issues) [51 – 53], chemotherapy (systemic efficacy limited by toxicity and drug resistance) [8, 53], and targeted therapy (e.g., bevacizumab improving survival in combination therapy) [5,54].”
PARP inhibition in prostate cancer
Nientiedt, C., Duensing, A. U., Zschäbitz, S., Jäger, D., Hohenfellner, M., Stenzinger, A., & Duensing, S. M. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22903 · Cited by 10
“Among the first of these mechanisms that was discovered, initially in breast and ovarian cancer but later also in prostate cancer, is the occurrence of reversion mutations to restore BRCA1 or BRCA2 function.(45,46) Remarkably, more than 10 of such reversion mutations to restore the open reading frame of BRCA2 have bee…”
BackgroundNgoi, N. Y. L., Tay, D., Heong, V. Y. M., Thian, Y. L., Ong, P. Y., Ow, S. G. W., Jeyasekharan, A. D. D., Lim, Y. W., Lim, S. E., Lee, S. C., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00008 · Cited by 8
Self-citationGhosh, M., Kang, M. S., Katuwal, N. B., Hong, S. D., Jeong, Y. G., Park, S. M., Kim, S., & Moon, Y. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317086 · Cited by 7
“…the therapeutic perspective, cancer cells with BRCA1/2 mutations are very sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors because PARP inhibitors cause an increase in DNA single-strand breaks, which are then converted to irreparable toxic DNA DSBs in those cells during replication [3].”
BackgroundLi, A., Sun, S., Song, T., Li, X., Cheng, W., Yao, R., Zhang, D., Cai, Z., Zhang, J., Zhai, D., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s162985 · Cited by 6
“efflux transporters such as PgP, and somatic mutations in BRCA genes leading to restoration of the open reading frame and thus BRCA function.(31) As far as we know, there is no report of resistance to PD-1/PD-L1 inhibitors.”
Lipid Polymeric Hybrid Nanoparticles: Formulation Techniques and Effects on Glioblastoma
Baghel, Y. S., & Bhattacharya, S. (2021) · Pharmaceutical Sciences · doi:10.34172/ps.2021.55 · Cited by 5
Current Advances in PARP1‐Targeted Theranostics
Tong, J., Chen, B., Volpi, T., Li, Y., Ellison, P. A., & Cai, Z. (2025) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4135 · Cited by 5
Kunihisa, T., Inubushi, S., Tanino, H., & Hoffman, R. M. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20458 · Cited by 5
Wang, Y., Wang, Y., Wang, N., You, L., Long, F., Shao, C., Wang, Y., & Wu, J. (2019) · Oncology Reports · doi:10.3892/or.2019.7242 · Cited by 5
“Given the evidence that primary and secondary resistance to PARP inhibition have led to treatment failure (21), the development of new biomarkers and the ability to identify potential mechanisms of resistance are vital.”
BackgroundReversal effect of quercetin on talazoparib resistance in BRCA1 mutant triple negative breast cancer
Eskiler, G. G., Çeçener, G., Egelí, Ü., & Tunca, B. (2019) · The European Research Journal · doi:10.18621/eurj.454176 · Cited by 3
“drug resistance (MDR) and epigenetic changes) to PARP inhibitors is a major clinical challenge in successful treatment [7-9].”
BackgroundPoly(ADP-ribose) Polymerase Inhibitors in Prostate Cancer: A Cornerstone in Precision Oncology
Ziadeh, T., & Kourié, H. R. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0119 · Cited by 5
Recent PARP Inhibitor Advancements in Cancer Therapy: A Review
Byran, G., Raj, P. P., Lakshmanan, K., Rajagopal, K., Krishnamurthy, P. T., & Palati, D. J. (2022) · Current Enzyme Inhibition · doi:10.2174/1573408018666220321115033 · Cited by 3
BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview
Gedeonová, D., Bianchi, C., Štembírek, J., Hrdinka, M., Chyra, Z., Buchtová, M., Hurník, P., Blažek, T., & Režnarová, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1528822 · Cited by 2
Adjuvant Therapy for Endometrial Cancer in the Era of Molecular Classification
Gupta, S., Gupta, R., Motwani, V., & Kalwaniya, D. S. (2024) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_88_24 · Cited by 2
“[55] Homologous recombination deficiency is frequently observed in the copy‑number‑high subclass of endometrial cancer.”
Lu, S., Gao, X., Li, X., Zhao, H., & Lu, H. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073343602240909115320 · Cited by 2
DNA Damage Repair Inhibitor for Breast Cancer Treatment
Min, A., Lee, K.-H., & Im, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_8 · Cited by 1
Coleman, R. L., & Ledermann, J. A. (2019) · European Oncology & Haematology · doi:10.17925/eoh.2019.15.1.29 · Cited by 1
Lorentzian, A. C., Rever, J., Ergin, E. K., Guo, M., Akella, N. M., Rolf, N., Lim, C. J., Reid, G. S. D., Maxwell, C. A., & Lange, P. F. (2022) · medRxiv · doi:10.1101/2022.03.04.22271927 · Cited by 1
“We selected to further characterize 220 PARP1 as a candidate target since PARP1/2 inhibitors are already developmental therapeutics 221 for a variety of pediatric tumors (13).”
BackgroundBhattacharjee, S., Sullivan, M. J., Wynn, R. R., Demagall, A., Hendrix, A. S., Sindhwani, P., Petros, F. G., & Nadiminty, N. (2022) · Figshare · doi:10.6084/m9.figshare.19408217
Bhattacharjee, S., Sullivan, M. J., Wynn, R. R., Demagall, A., Hendrix, A. S., Sindhwani, P., Petros, F. G., & Nadiminty, N. (2022) · Figshare · doi:10.6084/m9.figshare.19408211
Bhattacharjee, S., Sullivan, M. J., Wynn, R. R., Demagall, A., Hendrix, A. S., Sindhwani, P., Petros, F. G., & Nadiminty, N. (2022) · Figshare · doi:10.6084/m9.figshare.19408214
Ferroptosis as a novel targeted therapy in gynecological malignant tumors
Yu, C., Li, Y., Fu, Y., Yang, R., Nakevska, Z., Kumar, P. P., Tong, A. Y., Yang, N., Liu, D., Chen, C., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-04686-x
Metadata
- Authors
- Lim, J., & Tan, D. S. P.
- Affiliations
- National University Cancer Institute, Singapore (SG)
- Corresponding author
- Tan, David S. P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2017-08-22
- Volume
- 9
- Issue
- 8
- Pages
- 109
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC5575612
- OpenAlex
- W2750488721
- Cited by
- 52
- References
- 78
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 2 · 2022: 11 · 2021: 5 · 2020: 5 · 2019: 12 · 2018: 7 · 2017: 1
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- PARP inhibitors, synthetic lethality, homologous recombination deficiency, BRCA mutations, drug resistance mechanisms, predictive biomarkers, ovarian cancer, breast cancer, prostate cancer, combination therapy, immunotherapy, targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.